In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Vivo's 2016 Deals Of The Year: The Winners Are…

Executive Summary

We nominated 15 deals in three categories. You picked the winners. (Free article.)

Top Alliance: AstraZeneca's Asset Drop

Top Financing: It's A Tie!

  • 40% of you voted for the $474 million equity financing that mRNA drug developer Moderna Therapeutics LLC closed in September. And 40% voted for Samsung BioLogics'$2 billion IPO –a big validation for biologics development in South Korea and also a demonstration of the importance of diversification for parent Samsung.

Top M&A: QuintilesIMS: Big Merger In Big Data

  • 31% of you chose Quintiles' $9 billion merger with IMS Health. QuintilesIMS will have a market cap close to $18 billion, not to mention a huge head start in finding real-world evidence solutions for clients. Pfizer Inc.'s $14 billion buy of Medivation Inc. was a close second, with 29% of the vote.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV005012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel